Oramed Pharmaceuticals (NASDAQ:ORMP) said that all follow-up visits in its Phase 2b study of its oral insulin capsule, ORMD-0801, have been completed.
The double-blind, randomized Phase 2b study of 180 patients with Type 2 diabetes was initiated in mid-2015 and conducted at 33 clinical sites in the U.S.
The study was designed to generate ample data for both safety and efficacy endpoints. Top-line results are expected later this quarter.
